Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations. - PubMed - NCBI

Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations. - PubMed - NCBI

Genet Med. 2018 Jul 10. doi: 10.1038/s41436-018-0099-0. [Epub ahead of print]

Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations.

Issa AM1,2,3, Thorogood A4, Joly Y4, Knoppers BM4.

Author information

PMID:

 

29988078

 

DOI:

 

10.1038/s41436-018-0099-0